

## **SentreHEART Announces Participation at Heart Rhythm 2017**



May 09, 2017 09:32 AM Pacific Daylight Time

REDWOOD CITY, Calif.--(BUSINESS WIRE)--SentreHEART, Inc., the manufacturer of the LARIAT+® Suture Delivery Device and the new LARIAT-RS™ will be participating in the 2017 Heart Rhythm Scientific Sessions (HR 2017) being held in Chicago, Illinois May 10-13<sup>th</sup>.

The meeting's agenda will include several sessions dedicated to exploring device-based options for Left Atrial Appendage (LAA) closure in patients diagnosed with atrial fibrillation (AFib). Physician thought leaders in this field will be relating their experience and presenting data, which will include transpericardial LAA closure with the LARIAT in multiple AFib patient populations. Included at the HRS meeting is a dedicated Industry Expert Presentation, sponsored by SentreHEART, in Rhythm Theatre II on Thursday, May 11<sup>th</sup> highlighting the aMAZE Trial.

Studies have demonstrated the LARIAT not only closes the LAA mechanically<sup>1</sup> but may also isolate electrical activity within the LAA<sup>2</sup>. With a commitment to clinical evidence development, SentreHEART is presently sponsoring the FDA-approved, prospective, multi-center, randomized controlled trial known as the **aMAZE Trial**. The trial, unique in its superiority design, targets the most challenging AFib population of persistent and long-standing persistent AFib patients, is intended to demonstrate a LARIAT procedure for LAA closure, plus a subsequent PVI ablation will lead to a reduced incidence of recurrent AFib compared to PVI alone; with a high safety profile. Attendees of the HR 2017 who

are interested in learning more about the **aMAZE Trial** may attend the **Industry Expert Presentation (Thursday, May 11th Rhythm Theatre II)** or visit **SentreHEART's aMAZE Trial** booth #1635 in the Exhibit Hall throughout the meeting.

SentreHEART will also be highlighting the introduction of the LARIAT-RS, the fourth generation of LARIAT Suture Delivery Devices. The LARIAT-RS continues to improve upon the LARIAT+ device design featuring the complete snare retraction post-suture deployment and tightening, which enhances anatomic compatibility and ease of use during LARIAT procedures. For more information, visit SentreHEART booth #1635 at HR 2017 or learn more at [www.sentreheart.com](http://www.sentreheart.com).

## ABOUT SENTREHEART

SentreHEART is a privately owned medical device company based in Redwood City, CA. Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage. SentreHEART is the only company that offers both percutaneous and surgical options for immediate and complete LAA closure without the need for an implant.

aMAZE is an FDA-approved Trial – U.S. FDA IDE# G150107

Clinicaltrials.gov Identifier: NCT02513797

<sup>1</sup> Bartus K, et al. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients with Atrial Fibrillation. J Am Coll Cardiol 2013 Jul 9;62(2):108-18

<sup>2</sup> Han FT, et al. The Effects of LAA Ligation on Electrical Activity. Heart Rhythm. 2014 May; 11(5):864-70

## Contacts

SentreHEART, Inc.

Leslie J. Hines

[LHines@sentreheart.com](mailto:LHines@sentreheart.com)

[Tweets by @amazetrial](#)